Nyxoah Shares Drop 15% After Public Offering Launches
By Chris Wack Nyxoah shares were dropped after the company began a proposed underwritten public offering in the U.S. Shares were down 15% to $8.55 in recent trading. The stock hit its 52-week high o
Nyxoah Shares Are Trading Lower After the Company Announced the Pricing of a $50 Million Public Offering of 5,374,755 Shares at $9.25 per Share.
Nyxoah Shares Are Trading Lower After the Company Announced the Pricing of a $50 Million Public Offering of 5,374,755 Shares at $9.25 per Share.
Nyxoah Announces Pricing of Offering
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Pricing of Offering Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical
Oppenheimer Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $15
Oppenheimer analyst Suraj Kalia maintains $Nyxoah SA(NYXH.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 52.6% and a total
Nyxoah Announces Reduction of the Maximum Amount Available Under Its At The-Market Equity Offering Program
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET –
Nyxoah Announces Proposed Offering of Ordinary Shares
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a
Nyxoah Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Nyxoah Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Wall Street Set to Open Modestly Higher Wednesday as Inflation Dips in April
US stocks look set to open modestly higher Wednesday as key monthly inflation data came in slightly lower than expected, while annual inflation matched analyst forecasts. The Dow Jones Industrial Aver
OPEN, BCRX and AWIN Among Pre-market Gainers
Cantor Fitzgerald Adjusts Price Target on Nyxoah to $17 From $18, Maintains Overweight Rating
Cantor Fitzgerald Adjusts Price Target on Nyxoah to $17 From $18, Maintains Overweight Rating.
Oppenheimer Cuts Nyxoah Price Target to $15 From $20, Maintains Outperform Rating
Oppenheimer Cuts Nyxoah Price Target to $15 From $20, Maintains Outperform Rating.
Stifel Maintains Buy on Nyxoah, Maintains $27 Price Target
Stifel analyst Jonathan Block maintains Nyxoah with a Buy and maintains $27 price target.
Nyxoah SA | 6-K: Report of foreign private issuer (related to financial reporting)
Nyxoah Q1 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate, Sales $1.33M Beat $1.31M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 8.16 percent increase over losses of $(0.49) per s
Nyxoah 1Q Rev EUR1.22M >NYXH.BT
Nyxoah 1Q Rev EUR1.22M >NYXH.BT
Nyxoah Reports First Quarter 2024 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert,
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology
Invitation to Attend the Annual and the Extraordinary Shareholders' Meetings of the Company to Be Held on June 12, 2024
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the
Nyxoah SA Welcomes New Chief Medical Officer
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology
No Data